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To perform a systematic review andmeta-analysis of randomized controlled trials (RCT’s) reporting efﬁcacy of systematic treatments
approved for moderate-to-severe psoriasis by means of the Psoriasis Area And severity Index (PASI). We identiﬁed relevant articles
by systematic electronic searches (Cochrane Library, Medline,). Efﬁcacy was deﬁned as proportion of participants with
> 75% decrease in PASI (PASI-75) at primary efﬁcacy measurement (week8-16). PASI-75 response rates of double-blind
placebo-controlled trials were summarized as risk differences (RDs) and pooled using random effect models. Tolerability was assessed
from rates of withdrawals and adverse events. Twenty-one RCT’s totaling 7877 patients were analyzed qualitatively. Sixteen double-
blind placebo-controlled trials were eligible for meta-analysis. Inﬂiximab was signiﬁcantly superior to all other interventions (RD
77%, 95% conﬁdence interval (CI) 72-81%). Adalimumab (RD 64%, 95% CI 61-68%) was superior to efalizumab (RD 24%,
95% CI 19-30%). Etanercept 50 mg twice weekly (RD 44%, 95% CI 40-48%) and etanercept 25 mg twice weekly (RD 30%, 95%
CI 25-35%). Rates of withdrawals due to adverse events were highest for methotrexate and fumaric acid esters.
There are considerable differences in efﬁcacy between systemic biologic therapies which are approved for the treatment of mod-
erate-to-severe psoriasis. Inﬂiximab is most efﬁcacious, followed by adalimumab. Patients receiving inﬂiximab have an excess chance
of 77% over placebo to achieve PASI-75 response. Published evidence questions regulatory guidelines that recommend biologics as
second-line therapy for moderate-to-severe plaque psoriasis.
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Psoriasis is a common inﬂammatory skin disease, with estimate of
its world prevalence ranging from 0.5% to 4.6% and UK preva-
lence estimated at around1.5%.Theprevalence in thewholeKing-
domofSaudiArabiawasnotproperly studied.A studybyBenSaif
and Al-Shehab reported a frequency of 7%.1 A local study in the
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Furthermore, few studies have reported on the incidence of psori-
asis in the Middle East, including two small single-center studies,
conducted in 2004 found the incidence of psoriasis to be 3.4%, in
the south-western and eastern Saudi Arabia.3 Ethnic variations
have been identiﬁed and Caucasians are more likely to suffer from
thedisease.Chronicplaquepsoriasis is a lifelongdiseasewitha sub-
stantial impact on the physical well-being and quality of a patient’s
life. The course of psoriasis is variable and often unpredictable and
is characterized by periods of spontaneous remission and relapse.
Patients typically require long-term therapy in order to maintain
control of their disease. However, long-term treatment in patients
with moderate to severe psoriasis is limited by the potential for
toxic effects on organs, such as renal, hepatic or bone marrow, in
addition to teratogenicity and malignancies that are associated
with the traditional systemic therapies.4–6 Many dermatologists
are hesitant to aggressively treat moderate to severe psoriasis with
methotrexate, cyclosporine, oral retinoid, or psoralen-UVA be-
cause their administration requires frequent monitoring, and
serious adverse effects that limit their clinical utility.7
Psoriasis is one of the autoimmune diseases which is of par-
ticular interest. It is a chronic, relapsing and remitting inﬂam-
matory skin and joint disease that has a prevalence of 2–3%
worldwide.8
As with all autoimmune diseases, the pathophysiology of
psoriasis is complicated and not yet fully understood; however,
the signs and symptoms appear to be caused by hyperprolifer-
ation and inﬂammation of epidermal cells. In psoriasis, an
immunologic response involving T-lymphocytes and cytokines
alters the epidermal skin cell cycle resulting in psoriatic pla-
ques. Like other autoimmune diseases a mixture of genetic,
environmental, and behavioral inﬂuences are involved and/or
are associated with its development.9
Four biologic therapies (adalimumab, efalizumab, etaner-
cept and inﬂiximab) which had been thoroughly revised, are
now licensed for the treatment of moderate-to-severe psoria-
sis.4–6 Randomized double-blind, placebo controlled studies
have demonstrated short-term efﬁcacy and safety of all thera-
pies for psoriasis.10–12 However, these data may not reﬂect
practical day-to-day experience. Patients who need such biolo-
gics are those who are suffering from the most severe forms of
psoriasis. However, combinations of traditional systemic and
biologic therapies may be required.
Non-biologic therapy in psoriasis
Although topical treatments are sufﬁcient for many patients,
some need additional systemic drugs. These drugs have a po-
tential for serious side effects, such as hepatotoxicity and neph-
rotoxicity (methotrexate, cyclosporine) teratogenicity (oral
retinoids), and skin cancer (photo/chemotherapy), which limits
their long-term use.13 The current management of severe pso-
riasis is based on the principles of rotational therapy, which
stresses frequent alternations in treatment approaches in order
to reduce the cumulative risk of side effects.14 The choice of
treatment is inﬂuenced by short-term as well as long-term con-
siderations, including the severity of the disease, the effective-
ness of a given medication and its side effects, the patient’s
quality of life, and the ease of treatment. New guidelines have
been proposed indicating that ultraviolet B (UVB) should be
tried ﬁrst, and if this proves to be ineffective, photochemother-
apy with psoralen-ultraviolet A (PUVA), should be given in
that order.15 Severe cases of psoriatic arthritis, which fail
non-steroidal anti-inﬂammatory drugs or that present with
polyarticular joint involvement or destructive progression,
are approached using systemic administration of many of the
disease-modifying antirheumatic drugs, which proved effective
in rheumatoid arthritis therapy, including methotrexate, sulfa-
salazine and cyclosporine.16 Intra-articular injection with cor-
ticosteroids has been used to treat psoriatic arthritis ﬂare-ups
when one or two joints are involved. Systemic administration
of corticosteroids is generally discouraged as they may exacer-
bate psoriasis skin lesions upon discontinuation.
Why do we need new therapies?
Current therapies are limited by their potential side effects as
mentioned above. A National Psoriasis Foundation survey
showed that only 26% of patients were satisﬁed with their cur-
rent therapy.17 Moreover, a UK survey showed that 44% of pa-
tients prefer systemic therapy to topical treatment, indicating
that new systemic drugs are needed to replace patient unfriendly
topical treatments.18 Treatments are time consuming and inef-
fective, and patients experience side effects as the most negative
aspect of current treatments. This is also reﬂected in the Quality
of Life research. There is ample evidence that psoriasis can have
a profound effect on patients’ functioning and well being.19
Biologicals
Biologicals are a set of different engineered proteins used to
modify immune reactions. Antibodies, fusion proteins and re-
combinant cytokines are examples of these biologicals. These
“biological response modiﬁers” are designated to modify
deﬁned (patho) physiological pathways that regulate pivotal
immunological processes such as lymphocyte activation, inter-
action with antigen-presenting cells and endothelial cells
(adhesion and migration) and production and action of cyto-Table 1: Biologic nomenclature based on structural classiﬁcation.
Suﬃx Deﬁnition Murine vs. human components
Ximab Chimeric monoclonal antibody Variable region from donor mouse mAb grafted onto acceptor human antibody
Zumab Humanized monoclonal antibody Complementarily determining region (COR) segments from variable region of
donor mouse mAb grafted onto acceptor human variable region
Umab Human monoclonal antibody Fully human mAb, no mouse components
Cept Receptor-antibody fusion protein N/A
From: Dermatologic Therapy-Vol.21, (Issue 2), pages 131–141.20
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they have long-term remittive effects. In addition, they may
have a favorable side effect proﬁle. The increased understand-
ing of the immunopathology of inﬂammatory skin diseases
such as psoriasis, together with development of biotechnology
has led to the rapid development of these engineered proteins
not only in dermatology but also in rheumatology, gastroen-
terology and transplantation medicine.
Nomenclature of biologicals
Although the generic names of the biologicals may be confus-
ing, a strict nomenclature has been applied. Generic names of
chimeric monoclonals end with -ximab, humanized monoclo-
nals end with -zumab and human monoclonal antibodies end
with -umab. Receptor-antibody fusion proteins end with -cept.
Biologicals can be divided into three main groups: monoclonal
antibodies, fusion proteins, and cytokines. These molecules re-
act mainly with cell surface molecules expressed selectively on
leukocytes or with molecules secreted by inﬂammatory cells
(Table 1).
Immunopathogenesis of psoriasis
The immunopathogenic pathways leading to the development
of a psoriatic plaque have been subject to extensive studies.
The morphology of lesional psoriatic skin is characterized
by epidermal thickness and a pronounced dermal vascular
plexus, and the presence of inﬂammatory cells in the superﬁ-
cial dermis and epidermis. Increasing evidence suggests that T
cells play a key role in the pathogenesis of psoriasis. It has
been shown by Bos et al. (1983) that the majority of the der-
mal inﬂammatory inﬁltrate consists of partially activated
CD4+ and CD8+ T cells.21 These cells express CD45RO
on the surface, indicating their effector/memory status.18
Most of the inﬁltrating T cells also express markers such as
the interleukin-2 receptor (CD25) and HLA-DR, indicating
respectively, early and mid-to-late activation.21 The key role
of T lymphocytes in the pathogenesis of psoriasis was sup-
ported by reported beneﬁcial effects of speciﬁc T cell targeted
therapies, such a cyclosporine A and more recently alefa-
cept.22 But how do T cells play role in the development of
a psoriatic plaque? To understand this process better, it can
be broken down into three separate steps: a) the activation
of T cells; (b) the migration of T cells into the skin lesion;
and (c) the release of cytokines by activated T cells in the
skin.
T cell activation
The initial T cell activation requires stimulation of the T cell
receptor (TCR) by the major histocompatibility complex
(MHC I or II) on the antigen-presenting cell (APC). The adhe-
sion of the T cell with the APC is facilitated by the interaction
or surface molecules, such as CD2 on the T cell with leukocyte
function associated antigen (LFA)-3 on the APC, or LFA-1
(CD11a) on the T cells with intercellular adhesion molecule
(ICAM)-1 on the APC.21 After the initial activation via the
TCR, a second, nonantigen speciﬁc signal is needed to com-
plete the activation. This costimulatory signal results from
interactions between molecules on the T cell and their ligands
on APCs, for example CD2/LFA-3, very late antigen 4 (VLA-
4)/vascular cell adhesion molecule 1 (VCAM-1), LFA-1/
1CAM-1, CD40/CD40L, and others.23–25 Simultaneous deliv-
ery of both signals is essential for T cell activation, and if
the co- stimulatory signal is inhibited, T cells can become unre-
sponsive or “anergic”.
T cell trafﬁcking
When activated, T cells obtain speciﬁc cell surface proteins
necessary for the migration from lymph nodes and blood
vessels to the skin. T cells must be slowed down in the
blood stream in order to be immobilized and be bound to
the endothelium. This process, called “tethering”, is medi-
ated by the glycoprotein cutaneous lymphocyte antigen
(CLA), which is expressed on the surface of activated T cells
in psoriasis.26 CLA is an adhesion molecule, which interacts
with E-selectin and P-selectin, which are strongly up-regu-
lated on the endothelium during cutaneous inﬂammation.27
A temporary binding of the selectins with the receptors on
the T cell surface creates a rolling motion, which slows
the T cell down.28 This allows the T cell to be exposed to
chemokines, which activate T cell surface proteins, such as
LFA-1 and VLA-4. These integrin receptors form high-afﬁn-
ity bonds with, respectively, ICAM-l and VCAM-l on endo-
thelial cells, resulting in an arrest of the rolling process and
the subsequent ﬂattening of the activated T cell, which facil-
itates the diapedesis of the T cell through the blood vessel
wall.29 After extravasations through the blood vessel wall,
skin-homing T cells migrate to the dermis and epidermis
in response to chemotactic gradients. The chemokines that
enhance T cell trafﬁcking are produced by endothelial cells,
keratinocytes, monocytes and Langerhans cells, and their re-
lease is stimulated by interferon (lFN)-c and tumor necrosis
factor (TNF).30
Cytokines
Activated T cells produce one of two types of cytokines. Type
1 T cells produce the pro-inﬂammatory cytokines such as inter-
leukin (lL)-2, IFN-c, and TNF-a, whereas type 2 T cells pro-
duce cytokines such as IL-5, IL-4, and IL-10. Activated T
cells isolated from psoriasis lesions showed a predominant type
1 cytokines proﬁle.30 Both CD4+ and CD8+ T cells can pro-
duce type 1 cytokines (e.g., IL-2, IFN-c and TNF-a).31 The
secretion of cytokines by activated T cells inﬂuences neighbor-
ing cells, such as keratinocytes and dendritic cells, which in
turn release additional cytokines, creating a chronic inﬂamma-
tory cascade.32 IFN-c has been shown to induce epidermal
hyperplasia when injected into nonlesional skin of psoriasis
patients.33 Also, IFN-c stimulates the expression of ICAM-l
by epidermal keratinocytes, facilitating the binding of T cells
to keratinocytes. TNF-a can induce the expression of adhesion
molecules, such as ICAM-l,34 and vascular growth factors,
such as vascular endothelial growth factor (VEGF) 35 in the
skin, promoting T cell trafﬁcking. In addition, TNF-a has
been demonstrated to increase the expression of IL-8, a mem-
ber of the CXC chemokine family, in keratinocytes, thereby
enhancing the inﬁltration of T cells into the epidermis.36 Obvi-
ously, blocking of TNF-a will lead to the improvement of signs
and symptoms of psoriasis, as have been demonstrated in clin-
ical trials with inﬂiximab, a chimeric IgG1 anti-TNF-a mono-
clonal antibody,37 and etanercept, a TNF-receptor-Ig fusion
protein.38
Tools for assessment of efﬁcacy
A clear deﬁnition of the severity of psoriasis is essential in or-
der to develop proper assessment tools for new therapeutic
modalities to be used for the disease. The usefulness of a given
therapy can only be evaluated, based on the changes in the
severity score during and after the application of treatment.
Markers for disease severity
A common method for evaluating the efﬁcacy of treatment
modalities in psoriasis is to use skin biopsies before, during,
or after therapy. In addition, markers of epidermal prolifera-
tion and differentiation and of inﬂammation39 and immune
cell activation40 are often used together with the simple HE-
stains and histopathological techniques.
Since psoriasis is an immunological disease driven by T
cells, markers such as soluble CD27 and soluble IL-2 receptor
(sIL-2R), which are shed from activated T cells into the periph-
eral circulation, have been performed.41 It was found that
there was a very strong correlation between the symptom score
(PASI,) and sIL-2R levels in the circulation in patients with
psoriasis.
Body surface area (BSA)
The severity of psoriasis is measured using various symptom
scores. Erythema may be measured using a chromometer, inﬁl-
tration using ultrasound, and body surface area (BSA) in-
volved using computer image analysis of photographs.
Body surface area is, in daily practice, calculated using the
rule of nine and using the palmar side of the patient’s hand as
an equivalent to 1% of his or her BSA (Table 2). In general, a
BSA under 5% indicates mild psoriasis, moderate is between
5% and 10%, and over 10% is considered severe. A study into
the interobserver validity of the BSA has shown that the per-
centages given vary widely, and that there is a general overes-
timation of the BSA involved, when compared to computer
image analysis.42
Psoriasis Area and Severity Index (PASI)
The most often used psoriasis score is the Psoriasis Area and
Severity Index (PASI),43 in which the body is divided into four
regions; the head and neck (H), the trunk (T), the upper
extremities (U), and the lower extremities (L). Individual com-
ponents of this scoring system, especially the grade of ery-
thema (E), inﬁltration (I), and desquamation (D), are used
for symptom score calculation. Erythema, inﬁltration and des-
quamation are measured on a scale of zero (none), one (slight),
two (moderate), three (severe), and four (very severe). The per-
centage of each area (A) involved is given a number from zero
(0% involved) to six (100% involved). The PASI formula then
is 0,1 (EH + IH + DH) AH + 0.3 (ET + IT + DT) AT + 0.2
(EU + Iu + Du) Au + 0.4 (EL + IL + DL) AL (Table 3).
The PASI suffers from the disadvantages of interobserver
variations may be substantial, although the intraobserver var-
iability is limited. Therefore, it is advised that the number of
investigators actually measuring PASI is limited, to one per
center.
The PASI is also used to give a general impression of pso-
riasis severity. In chronic plaque psoriasis, a PASI under eight
is designated as mild, between 8 and 12 is moderate, and over
12 is severe. In clinical trials involving the evaluation of treat-
ment modalities, efﬁcacy is often expressed as percentages of
patients reaching PASI reductions of 90%, 75%, and 50%.
For example, a very effective treatment would have a PASI
75 of 80% after 12 weeks of active therapy, indicating that
80% of patients have a PASI reduction of 75% after such a
period of treatment.
Biologics in psoriasis
See Appendix 1.
Efalizumab
Efalizumab (Raptiva; Genentech, Inc.) is a recombinant
humanized IgG1 monoclonal antibody that binds and blocks
the CDlla subunit of LFA-1 found on the surface of T-cells.
By binding to LFA-1, efalizumab blocks the psoriasis inﬂam-
matory pathway at three critical points: generation of signal
two to activate pathogenic memory T-cell formation, adher-
ence and extravasation of T-cells through the vasculature,
and activation of keratinocytes by T-cells to produce inﬂam-
matory cytokines.44
Efalizumab is recommended for patients with a high risk of
latent tuberculosis or demyelinating disease for whom anti-
TNF-a agents are contraindicated.45,46
Table 2: BSA: measurement of involved body surface area.
Rule of nine:
Head 9%
Trunk 36%
Arms (including armpits) 18%
Legs (including buttocks) 36%
Genitals 1%
100%
Hand 1%
From Ramsay B, Lawrence CM;. Br J Dermatol 1991;124:565–
570.45
Table 3: PASI: psoriasis area and severity index.
Four main body areas: H, T, U, L
Area of psoriatic involvement! area: 0-6: A
Erythema, inﬁltration, desquamation: 0-4: E, I, D
PASI =: 0,1 (EH+ IH+DH) AH
+0,3 (Er + IT + DT) AT
+0,2 (Eu + Iu + Du) Au
+0,4 (EL + IL +DL) AL
(Adapted from : SR Feldman, G G Krueger Ann Rheum Dis.
2005;64(Suppl. II):ii65–ii68. doi: 10.1136/ard.2004.031237.)46
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Patients are required to have an initial platelet count prior
to starting efalizumab. Platelet counts should then be evalu-
ated on a monthly basis for the ﬁrst 3 months, then every
3 months thereafter. In a phase III, multicenter, randomized,
double-blind, parallel-group, placebo-controlled trial, 556 pa-
tients with stable, moderate to severe plaque psoriasis were
randomized to receive either efalizumab 1 mg/kg SC or pla-
cebo weekly for 12 weeks. At 12 weeks, 27% of efalizumab-
treated patients and 4% of placebo treated patients achieved
PASI 75.47 In an open-label extension to this study, 516 of
the original 556 patients received 1 mg/kg efalizumab every
week for an additional 12 weeks. At the end of 24 weeks,
44% of patients who continued to receive 1 mg/kg efalizumab
and 24% of the placebo crossover group achieved PASI 75,
demonstrating an increased efﬁcacy of continuous efalizumab
administration.48 Common side effects noted with efalizumab
treatment include headache, chills, myalgia, fevers, elevated
alkaline phosphatase,49 and infection. A recent case-report
documented the onset of drug reaction with eosinophilia and
systemic symptoms to efalizumab administration.50
Efalizumab is contraindicated in patients with hypersensi-
tivity to the agent. Caution should be exercised in patients
who are elderly, immunosuppressed, thrombocytopenic,
receiving live vaccines, have a history of malignancy, or have
active infection. Efalizumab is rated under pregnancy category
C and should be discontinued upon pregnancy.51
Alefacept
Alefacept (Amevive; Astellas Tokyo, Japan) is a recombinant
fusion protein that combines the ﬁrst extracellular domain of
leukocyte functioning antigen-3 (LFA3) with the CHI and
CH2 domains of human IgG1.52 The LFA3 portion of alefa-
cept binds to CD2 of memory T-cells and prevents the gener-
ation of signal 2. Binding also induces apoptosis of these cells,
as the IgG1 portion of alefacept interacts with the FccRIII
receptor on natural killer and macrophage cells.53 Hence, the
body can continue to mount primary and secondary responses
to other neoantigens and responds to infections and vaccina-
tions appropriately.54
The recommended dosing regimen is 15 mg intramuscular
(IM) injections every week for 12 weeks, followed by a 12-week
drug-free interval, resumed by another 12-week course if CD4
counts remain above 250/lL. If CD4 counts drop below 250/
lL for 1 month, alefacept is to be discontinued.55
Clinical trials have demonstrated the efﬁcacy of alefacept.
In a phase III, randomized, double-blind, placebo-controlled,
parallel-group trial, 507 patients with chronic, moderate to se-
vere plaque psoriasis received 10 mg IM alefacept, 15 mg IM
alefacept, or placebo weekly for 12 weeks. At the end of
12 weeks, it was found that 33% of the 15 mg alefacept-trea-
ted, 28% of the 10 mg alefacept-treated, and 13% of the pla-
cebo-treated group achieved PASI 75. Of the patients
receiving 15 mg alefacept achieving PASI 75, 71% maintained
PASI 50 during the 12-week post-treatment observation
period.56
The most common side effects were found to include head-
ache, nasopharyngitis, inﬂuenza, upper respiratory tract infec-
tion, and pruritus. Serious side effects reported with the use of
this agent include lymphopenia, malignancy, infections requir-
ing hospitalization, liver injury including hepatitis and acute li-
ver failure, and cardiovascular events. There have been no
opportunistic infections or infection-related deaths reported
with alefacept treatments. Less than 2.5% of patients develop
treatment-related antibodies to alefacept.57
Alefacept is contraindicated in patients with known hyper-
sensitivity to the agent and patients with HIV. Alefacept is
considered a pregnancy category B agent.
Anti TNF-a agents
The TNF-a inhibitor class of biologics includes inﬂiximab, eta-
nercept, and adalimumab. These agents work on the cytokine le-
vel to decrease levels of TNF-a produced by macrophages,
monocytes, T lymphocytes, keratinocytes, and dendritic cells.58
TNF-a is found at elevated levels in active plaques, serum, and
synovial ﬂuids of patients with psoriasis.59 It promotes inﬂam-
mation by activating nuclear factor KB, inducing III /6/8, and
up-regulating adhesion molecules on endothelial cells.58 Block-
ing TNF-a therefore inhibits the inﬂammatory pathway central
to psoriatic disease development.
TNF-a function should theoretically impair the body’s de-
fense against infections and tumorigenesis, as this cytokine is
involved in the body’s innate immunity and natural killer/
CD8 lymphocyte-mediated destruction of tumor cells.57
Cases of opportunistic infection, granulomatous diseases,
and hepatitis B reactivation have been reported with all anti-
TNF-a agents.58 It appears that infection rates may be higher
in patients treated with inﬂiximab and adalimumab compared
to etanercept. Despite the increased risk of malignancy in trea-
ted patients, an FDA study concluded that lymphoma risk is
not increased with anti-TNF-a agents. Other serious adverse
events associated with this class of biologics include exacerba-
tion of congestive heart failure and demyelinating disease in
predisposed patients. Psoriasis ﬂares and eruptive guttate pso-
riasis have also been triggered as a result of treatment.60
Therefore, all patients should be screened for tuberculosis,
demyelinating disorders including optic neuritis, and cardiac
failure prior to starting treatment.61
Etanercept. Etanercept (Enbrel; Amgen, Thousand Oaks,
CA) is a receptor antibody fusion protein that combines the
human IgG1 Fc region with two TNF type II (p75) receptors.
In contrast to other anti-TNF-a agents that bind to soluble
and transmembrane TNF-a, etanercept binds to soluble
TNF-a and TNF-B (lymphotoxin-a), both of which are in-
volved in granuloma formation.61
It is also approved for the treatment of rheumatoid arthri-
tis, psoriatic arthritis, juvenile rheumatoid arthritis, and anky-
losing spondylitis.
The recommended dosing regimen for etanercept is 50 mg
SC twice weekly for 12 weeks, followed by 50 mg SC per week.
Etanercept should be discontinued if patients do not reach a
PASI 50 response by week 12.50 Clinical effects can be ex-
pected between 4 and 8 weeks.50
When using etanercept Blood Urea Nitrogen (BUN), creat-
inine, alanine aminotransferase/aspartate aminotransferase
(ALT/AST), Hepatitis B panel, b-HCG (in women of
childbearing potential), periodic complete blood count (CBC)
and erythrocyte sedimentation rate (ESR), and clinical fol-
low-up every 3 months are recommended.62
A phase III, double-blind, placebo-controlled, randomized,
multicenter study involving 618 patients with moderate to se-
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vere plaque psoriasis evaluated the long-term efﬁcacy of eta-
nercept treatment for up to 96 weeks.63 Patients were random-
ized to receive 50 mg biweekly SC etanercept or placebo in the
ﬁrst 12 weeks of the study. At week 12, 47% of etanercept-
treated patients and 5% of patients in the placebo group
achieved PASI 75.64 At week 13, all patients were placed on
50 mg SC etanercept biweekly for an additional 84 weeks.
Clinical efﬁcacy peaked at week 24 for both groups. At week
96, 52% of the original treatment group and 51% of the origi-
nal placebo group achieved PASI 75.
Common side effects of etanercept therapy include injection
site reactions, cough, URI symptoms, and headache. More
serious side effects reported with etanercept include infections,
leukopenia, pancytopenia, CNS demyelinating disease, lym-
phoma, congestive heart failure exacerbation, and tuberculosis
reactivation.
Etanercept is contraindicated in patients with a known
hypersensitivity to the agent or active sepsis. Caution should
be advised for patients with a history of CNS demyelinating
disease, blood dyscrasia, malignancy, and congestive heart
failure.
Inﬂiximab. Inﬂiximab (Remicade, Centocor, Malvern, PA)
is an anti-TNF-a chimeric monoclonal IgG1 antibody. In
addition to blocking soluble TNF-a, inﬂiximab is also capable
of binding transmembrane TNF-a, resulting in complement
ﬁxation and antibody-mediated cytolysis.57
It received FDA approval for the treatment of rheumatoid
arthritis, Crohn’s disease, ankylosing spondylitis, and psoriatic
arthritis. Given inﬂiximab’s characteristic rapid onset of action
and high response rates, it is recommended when rapid disease
control is required in unstable conditions such as erythroder-
mic or pustular psoriasis.44
The recommended dosing regimen for inﬂiximab is a
5 mg/kg IV infusion, to be repeated at 2, 6, and then every
8 weeks thereafter.65 Clinical effect can be expected in
1–2 weeks.57
The EXPRESS II trial was a randomized, double-blind trial
involving 835 patients that compared continuous versus inter-
mittent inﬂiximab therapy. Patients received either IV infu-
sions of 3 mg/kg inﬂiximab, 5 mg/kg inﬂiximab, or placebo
at weeks 0, 2, and 6 for the inductive phase. At week 14, pa-
tients were randomized to receive intermittent versus continu-
ous therapy (every 8 weeks) at the previous induction dose. At
week 10, 76% of 5 mg/kg inﬂiximab patients, 70% of 3 mg/kg
inﬂiximab patients, and 2% of placebo patients achieved PASI
75.57
Common side effects associated with inﬂiximab include
URI, headache, pruritus, and sinusitis. Neutralizing antibodies
against inﬂiximab develop in 23% of patients and appear to re-
duce the efﬁcacy of treatment over time.65
The risk of developing granulomatous infections is double
than that of etanercept.66 More cases of transaminitis and hep-
atotoxicity occur with patients on inﬂiximab than the other
anti-TNF-a agents.58
Inﬂiximab is contraindicated in patients who have known
hypersensitivity to the agent and congestive heart failure
(NYHA class III/IV) or jaundice. It is considered a pregnancy
category B agent.65
Adalimumab. Adalimumab (Humira; Abbott Laboratories,
Abbott Park, IL) is a fully human monoclonal IgG1 antibody
against TNF-a. When bound to transmembrane anti-TNF-a it
is also able to mediate complement induced cytolysis.62
Adalimumab is approved for the treatment of chronic, mod-
erate to severe plaque psoriasis. It is also FDA approved for the
treatment of psoriatic arthritis, rheumatoid arthritis, ankylosing
spondylitis, and Crohn’s disease.54,65 The recommended dosing
for adalimumab in psoriasis is 40 mg SC every 2 weeks.
The REVEAL trial, a phase III randomized, double-blind,
placebo-controlled, multicenter study involving 1212 patients
with moderate to severe plaque psoriasis compared effects of
continuous versus intermittent administration of adalimumab.
The trial was divided into three periods. From week 0–16 (per-
iod A), patients were randomized to receive 40 mg SC ada-
limumab versus placebo, with those patients achieving a
PASI 75 response eligible to proceed to the open-label phase
of week 17–33 (period B), whereby all patients received ada-
limumab 40 mg SC every other week. From week 33–52 (per-
iod C), patients who achieved PASI 75 during period B and
had received adalimumab in period A were randomized to re-
ceive placebo versus adalimumab 40 mg SC every other week.
Loss of response, as deﬁned by a less than 50% PASI reduc-
tion from baseline at week 33 or a six-point decrease from
week 33 PASI, was greater in those patients re-randomized
to placebo (28%) than in those patients who continued on ada-
limumab therapy (5%), suggesting beneﬁt of continuous over
intermittent adalimumab dosing.67
The most common side effects of adalimumab included
injection site reactions, headache, nasopharyngitis, increased
triglycerides, dyspepsia, nausea, URTI, and fatigue. Serious
side effects reported included hypersensitivity to the agent,
demyelinating disease, deep fungal and tuberculosis infections,
malignancy, lupus-like symptoms, and congestive heart failure
exacerbation. The REVEAL trial found increased incidence of
nonmelanoma skin cancers in treatment patients compared to
placebo patients.67 Transaminase elevation and pancytopenia
with adalimumab have also been reported.67
There are currently no listed contraindications for ada-
limumab. However, patients with known hypersensitivity to
the agent and active infections/sepsis should not be prescribed
adalimumab.67
Ustekinumab
Ustekinumab is a fully human monoclonal antibody targeting
HL-12/23. It does so by binding to their shared p-40 subunit,
therefore blocking the interaction with cognate receptors.68
This drug thus targets Th1 and Th17 arms of immunity, both
of which we now know are essential parts in the pathogenesis
of psoriasis. It is administered as a subcutaneous injection.
In an initialphase II trial evaluating the safety and efﬁcacy
of single and multiple doses of ustekinumab, 320 patients with
moderate-to-severe plaque psoriasis underwent randomization
to receive ustekinumab or placebo.69 Participants in the dou-
ble–blind, placebo-controlled, crossover trial were randomly
assigned to 5 groups, 64 patients each, receiving placebo or 1
or 4 doses of ustekinumab (one 45 mg dose, one 90 mg dose,
four weekly 45 mg doses, or four weekly 90 mg doses). At week
16, patients in the active treatment group a PGA> 3 received
additional injection of their originally assigned dose, and at
week 20, patients in the placebo group crossed over to receive
one 90 mg dose of the study drug. No additional or mainte-
nance therapy was given.
Efﬁcacy assessed at 12 weeks revealed PASI scores for all
groups, achieving 52% (45 mg x1), 59% (90 mg x1), 67%
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(45x 4) and 81% (90 mg x 4) in the ustekinumab group, as
compared with 2% in the control group which were statisti-
cally signiﬁcant. Responses were maintained through week
24 and started wearing off. Efﬁcacy in those patients who
crossed over to the treatment group at week 20 to receive
90 mg dose mirrored the improvements observed in individuals
originally assigned to the one 90 mg dose at baseline. Serious
adverse effects were not statistically different from control
(68).
Golimumab
Golimumab is a human monoclonal antibody that binds to tu-
mor necrosis factor alpha (TNF_alpha),-inhibiting its inﬂam-
matory effects. Golimumab is a human immunoglobulin
G1K monoclonal antibody binding with high afﬁnity and spec-
iﬁcity to both soluble and transmembrane forms of TNF-a,
thereby neutralizing their bioactivity by blocking the interac-
tion with TNF-a receptors.69 In a study comprising 2029 ser-
um golimumab concentrations from 337 patients
participating in the GO-REVEAL trial population, the phar-
macokinetics of subcutaneously administered golimumab (50
or 100 mg every 4 weeks) were analyzed.69
In a recent study, a total of 405 patients were randomized:
113 to placebo and 146 each to the Golimumab 50 mg and
100 mg groups. Mean changes in PSA-modiﬁed SHS from
baseline to week 24 for the combined Golimumab 50 mg and
100 mg group (0.09) and the golimumab 50 mg group
(0.16) were signiﬁcantly different versus placebo (0.27)
(P= 0.015 and P= 0.011, respectively). Radiographic beneﬁt
was maintained through week 52 with Golimumab. Clinical
efﬁcacy, including improvement in joint and skin responses
and physical function, was maintained through 1 year. The fre-
quency/types of adverse events were similar to those reported
through week 24.71
After treatment for 2 years, Golimumab was generally well-
tolerated, with 8.6% (34/394) of patients experiencing serious
side effects. Injection site reactions were reported in 8.9%
(35/394) of patients. There were few problems with infections
or neoplasm and no reports of tuberculosis.70
Appendix A
Table 4.
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